HCPLive Network

National Epilepsy Awareness Month

November is National Epilepsy Awareness Month (NEAM), which was established to “highlight the growing need for awareness about epilepsy” as a way to help “dispel myths about epilepsy, teach proper seizure first aid and improve the quality of life for all individuals, families, and friends with epilepsy.” Epilepsy.com Editor-in-Chief Robert Fisher, MD, PhD, wrote in the November newsletter that epilepsy “remains the most prevalent serious disorder that is able to affect people across the full spectrum of ages.”

People who have seizures not only experience pre- and post-seizure symptoms, they become afraid and embarrassed should they have a seizure in public. In a November 2000 issue of Epilepsy & Behavior, more than 1,000 epilepsy patients were asked what the worst thing is about having epilepsy, and the number-one answer was fear—fear of dying, losing their job, or having a seizure while driving—followed by humiliation. It doesn’t help that many neurologists will not prescribe generic versions of the more than 20 AEDs (if they’ve received FDA approval), because there may be a risk that their patients could have a “breakthrough” seizure due to “the disparity between how AEDs work and the FDA requirements for generic equivalents”; the FDA “allows for significant differences between [brand-name] and generic drugs.” This is where the cost of medication comes into play, as there are many patients who cannot afford the high cost of brand-name drugs.

The above are just some of the reasons why the results from a CDC study released in August requires attention, covered in a previous MDNGLive article.

Because there are so many epilepsy patients who are under-treated, programs like NEAM and The Epilepsy Phenome/Genome Project are essential.

“Misconceptions about epilepsy are widespread,” says Rosemarie Kobau, a behavioral scientist with the CDC’s Epilepsy Program, co-author of the study. “Until there’s better understanding—among physicians and the public alike—there’s unlikely to be much progress made.”


 


Related Article on HCPLive:

Black Box Warnings: 11 AEDs Are Evaluated


Additional Resource:

American Academy of Neurology Position Statement of the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
 

 

 



Further Reading
Assessment of long-term data on treatment utility demonstrates the effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate for multiple sclerosis.
Treatment with Sativex oromucosal spray produces significant reductions in spasticity in patients with multiple sclerosis (MS) compared with placebo, but researchers reported no significant difference between the two in neurophysiologic measures.
Results from the RADIANCE study show that treatment with the selective S1P1 receptor modulator RPC1063 is associated with significant reductions in GD-enhancing lesions on MRI, as well as new or enlarging T2 lesions, compared with placebo.
Patients treated for two years with a combination of glatiramer acetate and estriol experienced a one-third reduction in relapse rate compared with patients who received glatiramer acetate and placebo.
Patients with multiple sclerosis who received thrice-weekly injections of glatiramer acetate 40 mg/ml reported increased satisfaction with their treatment and experienced lower rates of moderate and severe injections site reactions and other adverse events.
Five-year data from the ENDORSE study shows that patients with multiple sclerosis who continued treatment, or who switched from another medication, experienced improved NEDA outcomes.
Mikkel Anthonisan, MD, highlights his experience as the founder of Oceans of Hope, a global voyage to change the perception of multiple sclerosis, at the 2014 Joint ACTRIMS-ECTRIMS Meeting.
More Reading